Sigara Bağımlılığı ve Tedavisi
Özet
Sigara bağımlılığı, önlenebilir ölümlerin en başında gelen küresel ve kritik bir halk sağlığı problemidir. Dinamik ve reaktif yapısındaki tütün dumanı, içerdiği nikotin, katran ve karbonmonoksit gibi binlerce toksik kimyasal bileşenle hücresel, genetik ve kardiyovasküler düzeyde ciddi zararlar doğurmaktadır. Fiziksel ve psikolojik süreçleri barındıran bağımlılık mekanizmasında ana molekül nikotindir; nAChR reseptörlerine bağlanarak dopamin salınımını tetikler ve nöroadaptasyon oluşturur. Sigaranın bırakılması durumunda ise hedonik düzensizlik ve çeşitli yoksunluk belirtileri ortaya çıkmaktadır. Tedavi yaklaşımlarında başarı şansını artırmak için çok boyutlu bir strateji şarttır. Bu doğrultuda, istekli hastalara 5A, isteksiz olanlara ise 5R davranışsal ve bilişsel yönetim planları uygulanmaktadır. Davranışçı ve psikososyal yöntemler, süreci kolaylaştırmak adına nikotin replasman tedavisi (sakız, bant), vareniklin, bupropion ve sitizin gibi birinci basamak farmakolojik tedavi seçenekleriyle desteklenmelidir. Bağımlılık düzeyinin nesnel tespiti için Fagerström testinden, tanı kriterleri içinse DSM-V yönergelerinden faydalanılmaktadır. Birinci basamak sağlık hizmetlerinin önderliğinde yürütülen sigara bırakma poliklinikleri, çocuk yaştaki başlangıçları önlemeyi hedefleyen kalıcı devlet politikaları ve DSÖ'nün evrensel MPOWER stratejisi, tütünle mücadelede başarının kalıcı olmasını sağlayan temel yapı taşlarıdır.
Smoking addiction is a critical global public health issue that stands as the leading cause of preventable deaths, inducing physical and psychological dependency primarily through nicotine, which binds to nAChR receptors to trigger dopamine release and neuroadaptation. Tobacco smoke contains thousands of toxic and carcinogenic chemicals, including nicotine, tar, and carbon monoxide, causing severe cellular, genetic, respiratory, and cardiovascular damage. Cessation leads to nicotine withdrawal symptoms and hedonic deregulation, requiring a multi-dimensional approach where behavioral and cognitive strategies like the 5A plan for motivated patients and the 5R plan for unmotivated ones are utilized. To enhance cessation success, these psychosocial interventions must be combined with first-line pharmacological treatments such as nicotine replacement therapies (gums, patches), vareniklin, bupropion, or cytisine. Objective dependence levels are measured via the Fagerström test, while diagnostic criteria follow DSM-V guidelines. Ultimately, sustainable tobacco control relies heavily on primary care supervision, specialized smoking cessation clinics, robust state policies aimed at preventing youth initiation, and the comprehensive implementation of the WHO’s universal MPOWER package across all healthcare levels.
Referanslar
Carmody TP. Affect regulation, nicotine addiction, and smoking cessation†. J Psychoactive Drugs. 1989;21(3):331–42.
Hoffmann D, Hoffmann I. The changing cigarette, 1950-1995. J Toxicol Environ Health. 1997;50(4):307–64.
West R. Tobacco smoking: Health impact, prevalence, correlates and interventions. Psychol Heal [Internet]. 2017;32(8):1018–36. Available from: https://doi.org/10.1080/08870446.2017.1325890
TÜİK Türkiye ’ de Sigara Ve Tütün Mamülleri Kullanımı. 2019; Available from: https://www.verikaynagi.com/grafik/sigara-kullanimina-gore-dagilim-2019/
Prokhorov A V., Hudmon KS, Stancic N. Adolescent smoking: Epidemiology and approaches for achieving cessation. Pediatr Drugs. 2003;5(1):1–10.
Ekezie W, Murray RL, Agrawal S, et al. Quality of smoking cessation advice in guidelines of tobacco-related diseases: An updated systematic review. Clin Med J R Coll Physicians London. 2020;20(6):551–9.
Neuman MD, Bitton A, Glantz SA. Tobacco industry influence on the definition of tobacco related disorders by the American Psychiatric Association. Tob Control. 2005;14(5):328–37.
Hayrullahoğlu B. Success of Excise Duty on Tobacco Products and Alcoholic Beverages in Turkey. (11):89–112.
Polosa R. Examining the evidence for the health impact of combustion-free products: progress and prospects for tobacco harm reversal and reduction. Vol. 16, Internal and Emergency Medicine. 2021. p. 2043–6.
Jao NC. Menthol cigarettes, tobacco dependence, and smoking persistence: The need to examine enhanced cognitive functioning as a neuropsychological mechanism. Cad Saude Publica [Internet]. 2020;12(1):1–30. Available from: http://dx.doi.org/10.1016/j.ijpara.2016.09.005%0Ahttp://dx.doi.org/10.1016/j.vaccine.2015.09.060
Marques P, Piqueras L, Sanz MJ. An updated overview of e-cigarette impact on human health. Respir Res [Internet]. 2021;22(1):1–14. Available from: https://doi.org/10.1186/s12931-021-01737-5
Greaves L, Oliffe JL, Ponic P, et al. Unclean fathers, responsible men: Smoking, stigma and fatherhood. Heal Sociol Rev. 2010;19(4):522–33.
Baker TB, Mccarthy DE. Smoking Treatment: A Report Card on Progress and Challenges. Annu Rev Clin Psychol. 2021;17:1–30.
Papadakis S, Pipe A, Kelly S, et al. A. Strategies to improve the delivery of tobacco use treatment in primary care practice. Cochrane Database Syst Rev. 2015;2015(3).
Talhout R, Schulz T, Florek E, vet al. Hazardous compounds in tobacco smoke. Int J Environ Res Public Health. 2011;8(2):613–28.
Ballbè M, Martínez-Sánchez JM, Sureda X, et al. Cigarettes vs. e-cigarettes: Passive exposure at home measured by means of airborne marker and biomarkers. Environ Res [Internet]. 2014;135:76–80. Available from: http://dx.doi.org/10.1016/j.envres.2014.09.005
Matt GE, Quintana PJE, Destaillats H, et al. Thirdhand tobacco smoke: Emerging evidence and arguments for a multidisciplinary research agenda. Environ Health Perspect. 2011;119(9):1218–26.
Claire SS, Gouda H, Schotte K, et al. Lung health, tobacco, and related products: Gaps, challenges, new threats, and suggested research. Am J Physiol - Lung Cell Mol Physiol. 2020;318(5):L1004–7.
Le Houezec J, Mcneill A, Britton J. Tobacco, nicotine and harm reduction. Drug Alcohol Rev. 2011;30(2):119–23.
Overbeek DL, Kass AP, Chiel LE, Boyer EW, Casey AMH. A review of toxic effects of electronic cigarettes/vaping in adolescents and young adults. Crit Rev Toxicol [Internet]. 2020;50(6):531–8. Available from: https://doi.org/10.1080/10408444.2020.1794443
Burns DM, Dybing E, Gray N, et al. Mandated lowering of toxicants in cigarette smoke: A description of the World Health Organization TobReg proposal. Tob Control. 2008;17(2):132–41.
Eldridge AC, McAdam KG, Betson TR, et al. Impact assessment of WHO TobReg proposals for mandated lowering of selected mainstream cigarette smoke toxicants. Regul Toxicol Pharmacol. 2017;86:332-348.
Löfroth G. Environmental tobacco smoke: overview of chemical composition and genotoxic components. Mutat Res Toxicol. 1989;222(2):73–80.
Stellman SD, Djordjevic M V. Monitoring the tobacco use epidemic II. The agent: Current and emerging tobacco products. Prev Med (Baltim) [Internet]. 2009;48(1 SUPPL. 1):S11–5. Available from: http://dx.doi.org/10.1016/j.ypmed.2008.09.004
Bhatnagar A. Water Pipe (Hookah) Smoking and Cardiovascular Disease Risk: A Scientific Statement From the American Heart Association. Vol. 176, Physiology & behavior. 2016. 139–148 p.
Benowitz NL. Clinical pharmacology of nicotine: Implications for understanding, preventing, and treating tobacco addiction. Clin Pharmacol Ther. 2008;83(4):531–41.
Fowler CD, Turner JR, Imad Damaj M. Molecular mechanisms associated with nicotine pharmacology and dependence. Handb Exp Pharmacol. 2020;258:373–93.
Picciotto MR. Molecules and circuits involved in nicotine addiction: the many faces of smoking. Mol Cell Biochem. 2012;23(1):1–7.
Benowitz NL. Pharmacology of nicotine: Addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol. 2009;49:57–71.
Ton HT, Smart AE, Aguilar BL, et al. Menthol enhances the desensitization of human α3β4 nicotinic acetylcholine receptors. Mol Pharmacol. 2015;88(2):256–64.
Giulietti F, Filipponi A, Rosettani G, et al. Pharmacological Approach to Smoking Cessation: An Updated Review for Daily Clinical Practice. High Blood Press Cardiovasc Prev [Internet]. 2020;27(5):349–62. Available from: https://doi.org/10.1007/s40292-020-00396-9
Hezer H, Karalezli A. The Effect of Psychological Dependence on Smoking Urge and Nicotine Withdrawal Symptoms. Ankara Med J. 2019;19(4):700–7.
Hughes JR. Motivating and Helping Smokers to Stop Smoking. J Gen Intern Med. 2003;18(12):1053–7.
Wills L, Kenny PJ. Addiction-related neuroadaptations following chronic nicotine exposure. J Neurochem. 2021 Jun;157(5):1652-1673. doi: 10.1111/jnc.15356.
Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991;(9):1119-27. doi: 10.1111/j.1360-0443.1991.tb01879.x.
American Psychiatric Association. Tobacco related disorders. In:Diagnostic and Statistical Manual of Mental Disorders 5.Ed.DSM-5. American Psychiatric publishing Washington, DC, London, England (2014):571-577.
Steliga MA. Smoking Cessation in Clinical Practice: How to Get Patients to Stop. Semin Thorac Cardiovasc Surg [Internet]. 2018;30(1):87–91. Available from: https://doi.org/10.1053/j.semtcvs.2018.02.033
Chen H, Zhao B, Li X, et al. Nicotine Dependence, Perceived Behavioral Control, Descriptive Quitting Norms, and Intentions to Quit Smoking among Chinese Male Regular Smokers. Subst Use Misuse [Internet]. 2021;56(1):145–52. Available from: https://doi.org/10.1080/10826084.2020.1846195
Prochaska JO, Goldstein MG. Process of smoking cessation. Implications for clinicians. Clin Chest Med. 1991;12(4):727-35.
Bricker JB, Watson NL, Mull KE, et al. Efficacy of Smartphone Applications for Smoking Cessation: A Randomized Clinical Trial. JAMA Intern Med. 2020 Nov 1;180(11):1472-1480. doi: 10.1001/jamainternmed.2020.4055.
Zwar NA. Smoking cessation. Aust J Gen Pract. 2020;49(8):474–81.
Crooks PA, Bardo MT, Dwoskin LP. Nicotinic receptor antagonists as treatments for nicotine abuse. Adv Pharmacol. 2014;69:513-51. doi: 10.1016/B978-0-12-420118-7.00013-5.
Cahill K, Lindson-Hawley N, Thomas KH, et al. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2016;2016(5).
Kalkhoran S, Glantz SA. E-cigarettes and smoking cessation in real-world and clinical settings: a systematic review and meta-analysis. Lancet Respir Med. 2016;4(2):116-28. doi: 10.1016/S2213-2600(15)00521-4. Epub 2016 Jan 14.
Soiza RL, Donaldson AIC, Myint PK. Vaccine against arteriosclerosis: an update. Ther Adv Vaccines. 2018;9(6):259–61.
Howes S, Hartmann-Boyce J, Livingstone-Banks J, et al. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2020 Apr 22;4(4):CD000031. doi: 10.1002/14651858.CD000031.pub5.
King DP, Paciga S, Pickering E, et al. Smoking cessation pharmacogenetics: Analysis of varenicline and bupropion in placebo-controlled clinical trials. Neuropsychopharmacology [Internet]. 2012;37(3):641–50. Available from: http://dx.doi.org/10.1038/npp.2011.232
Garcia-Gomez L, Hernández-Perez A, Noe-Diaz V, et al. Smoking cessation treatments: Current psychological and pharmacological options. Rev Investig Clin. 2019;71(1):7–16.
Türk Toraks Derneği. Tütün Kontrolü Çalışma Grubu. Si̇gara birakma tani ve tedavi̇ uzlaşi raporu. Miki Basımevi. Ankara, 2014.
Tutka P, Vinnikov D, Courtney RJ, et al. Cytisine for nicotine addiction treatment: a review of pharmacology, therapeutics and an update of clinical trial evidence for smoking cessation. Addiction. 2019;114(11):1951–69.
Bar-Zeev Y, Lim LL, Bonevski B, et al. Nicotine replacement therapy for smoking cessation during pregnancy. Med J Aust. 2018;208(1):46–51.
Jang S, Park S, Jang BH, et al. Study protocol of a pragmatic, randomised controlled pilot trial: Clinical effectiveness on smoking cessation of traditional and complementary medicine interventions, including acupuncture and aromatherapy, in combination with nicotine replacement therapy. BMJ Open. 2017;7(5):1–7.
World Health Organization, & Research for International Tobacco Control. (2008). WHO report on the global tobacco epidemic, 2008: the MPOWER package. World Health Organization
